Research reportSubthreshold symptoms and time to relapse/recurrence in a community cohort of bipolar disorder outpatients
Introduction
Bipolar disorder (BD) is a chronic disorder, and new episodes are frequent even in regularly followed patients under standard psychiatric treatment (Perlis et al., 2006). There is now strong evidence of progressive neuropathological processes in BD, changes that could explain some of the clinical and cognitive features of this disease (Berk et al., 2010), and they seem to be more profound in patients with multiple prior episodes or longer illness duration. Therefore, recognizing factors related to increased risk of relapse of a previous affective disorder, or to the appearance of a new affective episode (recurrence), seems crucial.
In several previous studies, subthreshold (subsyndromal) symptoms have been associated with an increased risk of affective relapse/recurrence (Goodnick et al., 1987, Keller et al., 1992, Kleindienst and Greil, 2002, Perlis et al., 2006, Tohen et al., 2006, Tohen et al., 2003). In a naturalistic and prolonged study, the predictive value of subsyndromal symptoms on time to relapse/recurrence was reviewed in a systematic and prospective manner (Judd et al., 2008). That research was done mainly – although not exclusively – in tertiary care centers and has not been replicated. In that study, participants recovering with subsyndromal affective symptoms experienced subsequent major affective episodes earlier than asymptomatic recoverers, and recovery status was the strongest correlate of time to episode recurrence. But the setting of care may have an impact on course and outcome of BD patients. Recent research points to possible differences between EU and U.S. sites, with lower morbidity in EU patients (De Dios et al., 2010, Baldessarini et al., 2010); hence, the possibility of considering the two populations as heterogeneous for future pharmacological studies has been proposed (Post et al., 2011).
The primary objective of our study was to analyze the influence of subsyndromal affective symptoms on time to affective relapse/recurrence in a cohort of non-US bipolar psychiatric outpatients from the community. We tested the hypothesis that BD psychiatric outpatients who are clinically in euthymia but with residual subsyndromal affective symptoms would return to a subsequent major affective episode significantly faster than those completely asymptomatic at baseline. Secondarily, we have studied other clinical and socio-demographic variables related to time to relapse/recurrence.
Section snippets
Study overview
This study is part of an ongoing prospective, naturalistic, longitudinal follow-up research on the course and outcome of a cohort of bipolar disorder outpatients regularly attended in the public General Health System in Madrid (Spain). The main objective and details of the study protocol have been described in detail elsewhere (De Dios et al., 2010). Consecutive bipolar patients are recruited in three outpatient clinics, two of them in mental health centers and one in a general hospital. The
Primary end-points
Participants were divided into 2 groups applying pre-specified psychometric criteria: those fully euthymic at baseline and those who retained ongoing subsyndromal affective symptoms. Analysis focused on the period from the baseline clinically euthymic status until the onset of the first affective relapse/recurrence (first well interval). Affective relapse/recurrence was considered to be present if hospitalization was needed because of acute depression, mania or mixed episode, or whenever that
Results
Two hundred eighty-two BD patients were initially considered for the present study. Of them, 225 (79.8%) were clinically in euthymia and were included in the survival analysis (BD I, n=168; BD II, n=57). Applying psychometric criteria, 163 patients were euthymic (72.4%) and 62 (27.6%) subsyndromal at baseline. The majority of the baseline subsyndromal patients were depressive (47 patients, 75.8%). As to socio-demographic data, 117 (52%) were females; mean age was 48.6 years (95% CI, 46.7–50.5).
Discussion
We analyzed time to affective relapse/recurrence in bipolar disorder outpatients with subsyndromal symptoms, as compared with those completely asymptomatic, followed for up to five years in a non-tertiary outpatient setting in Spain.
Patients with subsyndromal symptoms experienced an affective relapse/recurrence faster than completely asymptomatic ones (median time 35 weeks vs. 109), and had 1.7 times higher risk of having a new major affective episode. Despite methodological differences, we
Conclusions
Several studies point to possible differences in the morbidity, course and outcome of BD patients according to the setting of patient care. Nevertheless, our results show that in a Spanish non-tertiary BD cohort, subsyndromal BD symptoms and psychosocial stress at baseline predict earlier affective episode relapse.
Role of funding source
Nothing declared.
Conflict of interest
Dr. C. de Dios has received grant support or given presentations for the following pharmaceutical companies: AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Janssen-Cilag, Pfizer, Glaxo-Smithkline, Cephalon and Lundbeck.
Dr. Ezquiaga has served as speaker for the following entities: AstraZeneca, Lundbeck, Sanofi-Aventis, and Boëhringer-Ingelheim.
Dr. Agud has served as speaker for Bristol-Myers-Otsuka and Lilly.
Prof. E. Vieta has received research grants, and served as consultant, advisor or
Acknowledgments
To our patients and their families.
References (31)
- et al.
Effects of stress and social support on recurrence in bipolar disorder
Journal of Affective Disorders
(2004) - et al.
Clinical and therapeutic implications of predominant polarity in bipolar disorder
Journal of Affective Disorders
(2006) - et al.
Time spent with symptoms in a cohort of bipolar disorder outpatients in Spain: a prospective, 18-month follow-up study
Journal of Affective Disorders
(2010) - et al.
The stress sensitization hypothesis: understanding the course of bipolar disorder
Journal of Affective Disorders
(2006) - et al.
Modification of the clinical global impressions (CGI) scale for use in bipolar illness (BP): the CGI-BP
Psychiatry Research
(1997) - et al.
Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression
Annals of Clinical Psychiatry
(2011) - et al.
Morbidity in 303 first-episode bipolar I disorder patients
Bipolar Disorder
(2010) - et al.
Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention
Bipolar Disorder
(2011) - et al.
Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors
Neuroscience & Biobehavioral Reviews
(2010) - et al.
Development and validation of a social functioning scale, the social adaptation self-evaluation scale
European Neuropsychopharmacology
(1997)
Life events and the course of bipolar disorder
American Journal of Psychiatry
Relapse and impairment in bipolar disorder
American Journal of Psychiatry
Inter-episode major and subclinical symptoms in affective disorder
Acta Psychiatrica Scandinavica
A rating scale for depression
Journal of Neurology, Neurosurgery & Psychiatry
Stress reactivity in bipolar patients and its relation to prior history of disorder
American Journal of Psychiatry
Cited by (0)
- 1
Tel.: +34 91 520 22 00.
- 2
Tel.: +34 914818000.
- 3
Tel.: +34 916300480; fax: 916303668.
- 4
Tel.: +34 91 313 55.